One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling

One Biosciences announces €15 Million Series A financing

One Biosciences has announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures.

One Biosciences raises €15 million to advance single-cell oncology platform

Funding to accelerate development of AI-driven tumour profiling tool OneMap

One Biosciences Raises €15M Series A to Boost AI-Driven Cell Profiling - AI-Tech Park

Funding will be used to establish the clinical utility of OneMap, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trials Proceeds will also help scale strategic partnerships with pharmaceutical and biotechnology companies Financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Ad…

One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling – Optimum Strategic CommunicationsLink to: Hot topic: A patently obvious opportunity?Link to: Xeltis announces positive data for Xabg, its coronary artery b

Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trials Proceeds will also help scale strategic partnerships with pharmaceutical and biotechnology companies Financing led by Redmile Group and Blast, with participation […]

One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling

Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trialsProceeds will also help scale strategic partnerships…